ICON plc downgraded by Goldman with a new price target
$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Goldman downgraded ICON plc from Buy to Neutral and set a new price target of $200.00 from $250.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $236.00 | Neutral → Buy | Rothschild & Co Redburn |
| 8/21/2025 | $200.00 | Buy → Neutral | Citigroup |
| 7/24/2025 | $224.00 | Neutral → Outperform | Robert W. Baird |
| 4/29/2025 | $150.00 | Overweight → Neutral | Analyst |
| 4/14/2025 | $157.00 | Buy → Hold | TD Cowen |
| 4/10/2025 | $165.00 | Overweight → Equal Weight | Barclays |
| 3/21/2025 | $250.00 → $200.00 | Buy → Neutral | Goldman |
| 1/7/2025 | $263.00 | Outperform | RBC Capital Mkts |
ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Barry Balfe, COO of ICON plc, will present at the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 1:25 pm ET and Dr. Steve Cutler, CEO of ICON plc, will participate at the Deutsche Bank 2025 Healthcare Summit on Thursday, September 11, 2025. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we adva
ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION TOTAL NUMBER OF VOTES VOTE FOR VOTE AGAINST VOTE WITHHELD 1.1
Rothschild & Co Redburn upgraded ICON plc from Neutral to Buy and set a new price target of $236.00
Citigroup downgraded ICON plc from Buy to Neutral and set a new price target of $200.00
Robert W. Baird upgraded ICON plc from Neutral to Outperform and set a new price target of $224.00
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the
ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION TOTAL NUMBER OF VOTES VOTE FOR VOTE AGAINST VOTE WITHHELD 1.1
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC
Highlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02. Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025. Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share. Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025. Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share. Net de
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical researc
Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)